Women's Experiences in Injectable Opioid Agonist Treatment Programs in Vancouver, Canada





Samara Mayer

Doctoral student, University of British Columbia **Research Coordinator,** British Columbia Centre on Substance Use I respectfully acknowledge that I live and work on the stolen lands of the Coast Salish, Musqueam and Tsleil-Waututh Nations. Thank you to Jules Chapman, Nancy McDonald and to the women who participated in this study and provided feedback on the results.

Thank you to the iOAT programs for their support in implementing this study.

Thank you to my co-authors; Jade Boyd, Nadia Fairbairn, Isabella Brohman, Jules Chapman, Emily Jenkins and Ryan McNeil This study was funded by the US National Institutes of Health [Grant # R01DA044181; R01DA043408] and a Canadian Institute of Health Research Doctoral Fellowship.





Overview

- Background
- Study Objectives
- What is iOAT?
- Study sites
- Methods
- Study Findings



International Journal of Drug Policy Volume 117, July 2023, 104054

DRUG POLICY

Research Paper

Women's experiences in injectable opioid agonist treatment programs in Vancouver, Canada

<u>Samara Mayer</u>^{a b}, <u>Jade Boyd</u>^{a c}, <u>Nadia Fairbairn</u>^{a c}, <u>Jules Chapman</u>^a, <u>Isabella Brohman</u>^a, <u>Emily Jenkins</u>^d, <u>Ryan McNeil</u>^{a c e f g} <u></u> ⊠

Show more 🗸

+ Add to Mendeley 😪 Share 🗦 Cite

https://doi.org/10.1016/j.drugpo.2023.104054 🥱

Get rights and content 🧵

Implications of Study Findings


Background

- Women's risk of violence and drug-use related harms has been amplified during the overdose crisis (Boyd et al. 2018, Mitra et al. 2020).
- Equitable access to a spectrum of opioid treatment, including injectable opioid agonist treatment (iOAT), holds the potential to help mitigate risks associated with an increasingly toxic illicit drug supply for women.
- Women face barriers to drug treatment programs and are **under-served and under-prioritized** in the delivery of gender-attentive treatment services (Lyons et al., 2016, Martin & Walia, 2019).
- **Previous research** on iOAT has highlighted some differences in retention and treatment outcomes between men and women (Oviedo-Joekes et al. 2010). For instance better health for women in iOAT meant rebuilding relationships and better self care (Palis et al. 2017).

Objectives


- To identify how women's **social context** impacts their engagement with iOAT.
- To identify how **structural aspects** of program delivery impact women's engagement with iOAT.


What is iOAT?



BC Centre on Substance Use (2017) Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder. https://www.bccsu.ca/wp-content/uploads/2021/07/BC_iOAT_Guideline.pdf

Research Context: Study Sites





Google maps image: Main and Hastings Street

Vancouver Downtown Eastside Local Areas. Downtown Eastside Plan. City of Vancouver (2018).

Methodology: Critical Ethnography and Critical Drug and Gender Studies

- Sixteen women participated in in-depth qualitative interviews (5 follow up interviews).
 - 2018-2020*
- **50 hours** of ethnographic observations.
- Follow up meetings with women who participated in interviews.



Participant demographics

Age Mean Range	44 22-58
Ethnicity Indigenous White	10 (62.5%) 6 (37.5%)
Sexual Orientation Straight Gay Bisexual	14 (87.5%) 1 (6.3%) 1 (6.3%)
Housing Apartment Single Room Occupancy Hotel (Private) Single Room Occupancy Hotel (Public) Friends Place Unsheltered/Outside	5 (31.25%) 1 (6.3%) 8 (50.0%) 1 (6.3%) 1 (6.3%)
Income Generation Sources (30 days) * Full-time employment Part-time employment Drug Selling Sex Work Recycling Boosting Vending Panhandling Social Assistance Other: Support from family, ex-husband	1 (6.25%) 5 (31.25%) 3 (18.75%) 3 (18.75%) 5 (31.25%) 3 (18.75%) 3 (18.75%) 1 (6.25%) 14 (87.50%) 3 (18.75%)

Study Findings: Personal Relationships and iOAT

 Enrolling women and their partners can encourage women's engagement in iOAT, but programs must accommodate these partnerships.

My ex-spouse and I have a no contact order now and we both go to the program. So, we had to work it with management, certain times for me to be able to go twice a day and certain times for him, so there's no running... we're not having to run in with each other and it was just, it was complicated at first, so I just chose to withdraw from the program for a couple of weeks.

Study Findings: Relationships with care providers

- Women built positive relationships with care providers and felt that iOAT was safer than other places (e.g., street, overdose prevention site).
- Program operations (e.g., lack of privacy, daily-witnessed dose administration) could strain relationships between care providers and women and did not account for their social context (e.g., housing, jobs, personal relationships).

Rules have been a relaxed here [...] like just observing the surroundings of who they're dealing with, you know. It's just not so medical, so clinical. More, yeah, like friendlier, yeah. It's just more, you know, 'hi, **how's it going?' and** you know, and engaged in people's lives and wanting to know. Not nosy, but wanting to know and giving a shit about what, you know, what's going on in people's lives.

Supporting medication administration

"I know, I can't believe that. That's just like, I really didn't expect them [nurses] to go so above and beyond, like they'll teach me like how to do that, like and I mean they literally had to sit with me. [...] The nurse said I think you'd have a more comfortable way of like positioning your hands..." "I didn't like IV'ing in front of other people, and that was a big thing, and there were discussions of your other medications, and the doctor wants to see you and are you going down this week, and it was just, like I just didn't want my recovery and its falls and dips to be discussed every day and not in any kind of privacy"

Findings: Agency and Control

 iOAT helped women gain more agency (e.g., more money, more control over drug use, better health).

Yeah, I was seeing this guy for a while and I think I liked him because he was a dealer. I could get my stuff for free, so I was, you know, seeking out dealers as boyfriends to keep the costs down. So... a change would be from like I had a partner, and now I don't. [Laughs], and that is my change. [Laughs] Yeah, he was a dealer, so I was getting all my jib for free, so. And down too, if I wanted it, yeah. But he was... he was... he was horrible. He was horrible and treated me bad, so yeah. Yeah, so I don't miss that, and I don't miss him.

Findings: Agency and Control

 Program requirements made it hard for women to live according to their terms (e.g., employment, (re) connecting with their family and children) because you could not take the medication home.

"Well, like it's hard to move forward any further, because we're not allowed carries. It's really difficult to...you know, it's hard to visit anybody. It's hard to go anywhere. Sometimes it's even hard to get to work on time because I always have to go to the clinic before I can go to work, and I can't go to work sick. That would be pointless. And torture. So yeah, so I'm kind of just stuck. Until they get more clinics, or they're more flexible on the dispensing of it, or whatever, I'm just stuck with what I have."

Limitations

- Specific to a particular context.
- COVID-19 limited follow up interviews and additional fieldwork.
- Targeted questions on mothering and motherhood no interview guide.
- Limited information on gender-diverse people.

Key message and recommendations

- Gender responsive, diverse and low-threshold treatment are needed and include; assistance with injection, enrolling partners, providing take home options, increasing privacy, and providing women's specific iOAT programs.
- iOAT programs need more support to build strong relationships with women, and to have the flexibility to adapt operations to meet women's diverse and changing social context and needs.
- Future programming should focus on how to foster women's **agency** in iOAT programs and provide support for **socio-structural** barriers they face.

Thank you for your time!

References:

Boyd, J., Collins, A. B., Mayer, S., Maher, L., Kerr, T., & McNeil, R. (2018). Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada. *Addiction*, *113*(12), 2261–2270.

CRISM. (2019). National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline. In <u>https://crism.ca/projects/ioat-guideline</u>. CRISM.

Lyons, T., Shannon, K., Richardson, L., Simo, A., Wood, E., & Kerr, T. (2016). Women who use drugs and have sex with women in a Canadian setting: barriers to treatment enrollment and exposure to violence and homelessness. Archives of Sexual Behavior, 45(6), 1403–1410.

Martin, C. M. & Walia H. (2019). Red Women Rising: Indigenous Women Survivors in Vancouver Downtown Eastside.

Mitra, S., Kolla, G., Bardwell, G., Wang, R., Sniderman, R., Mason, K., Werb, D., & Scheim, A. (2022). Requiring help injecting among people who inject drugs in Toronto, Canada: Characterising the need to address sociodemographic disparities and substance-use specific patterns. *Drug and Alcohol Review*.

Oviedo-Joekes, E., Guh, D., Brissette, S., Marchand, K., Marsh, D., Chettiar, J., Nosyk, B., Krausz, M., Anis, A., & Schechter, M. T. (2010). Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug and Alcohol Dependence, 111(1–2), 50–57.

Palis, H., Marchand, K., Guh, D., Brissette, S., Lock, K., MacDonald, S., Harrison, S., Anis, A. H., Krausz, M., & Marsh, D. C. (2017). Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder. Substance Abuse Treatment, Prevention, and Policy, 12(1), 1–12.